Ref ID: 18803
Author:
F. Cabello, DVM – Researcher, N. Marti, PhD – Drug Development Project Leader, D. Gargallo-Viola, PhD – Infectious Diseases Manager, A. Guglietta, PhD – R&D Director;
Author address:
Res. and Dev. Ctr.. Ferrer Internacional SA, Barcelona, Spain
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: Arasertaconazole nitrate is a new topical anti8209;mycotic molecule which has shown a wide spectrum of activity against yeasts, dermatophytes, moulds and clinically relevant bacterial. In this study, the in vivo therapeutic efficacy of arasertaconazole nitrate vaginal ovule was evaluated against an experimental vaginal infection model with Candida albicans. Methods: Ovariectomized and oestrus-induced rats were immunosuppressed with dexamethasone in the drinking water. Vaginal candidiasis was established by intravaginal inoculation of 107CFU of C.albicans ATCC44858. Rats (n = 5 per group) received a 3 days repeated intravaginal administration using a ovule with a fixed volume of 0.1 ml. Animals were administered once a day with Placebo, 6.25% or 25% of arasertaconazole nitrate. Antifungal efficacy was assessed by colony counts obtained from vaginal smears and by histological examination 24 h after last dose. Results: Animals treated with 6.25 % or 25% of Arasertaconazole nitrate showed marked therapeutic efficacy 24 h after the last dose. A good dose-response was observed with a fungal burden reduction (Mean ± SD log CFU/mL sample) of 2.61 ± 0.40 in 6.25% group and 3.32 ± 1.15 in 25% group. A good correlation between histological results and microbiological results was observed. No relevant fungal presence was detected in histological samples taken from 6.25 % or 25 % treated animals. Conclusion: Arasertaconazole nitrate has demonstrated a strong in vivo efficacy against C.albicans.
Abstract Number: M-980
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a